Mapping	O
of	O
B-cell	B-protein
epitopes	I-protein
of	O
the	O
human	B-protein
hepatitis	I-protein
B	I-protein
virus	I-protein
X	I-protein
protein	I-protein
.	O

The	O
immune	O
response	O
to	O
the	O
X	B-protein
protein	I-protein
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	B-protein
fusion	I-protein
proteins	I-protein
and	O
synthetic	O
peptides	O
.	O

Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O

Each	O
serum	O
contained	O
antibodies	B-protein
to	O
a	O
different	O
set	O
of	O
epitopes	B-protein
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	B-protein
sequence	I-protein
.	O

Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	B-protein
proteins	I-protein
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

The	O
carboxy-terminal	B-protein
half	I-protein
of	O
the	O
HBx	B-protein
protein	I-protein
was	O
preferentially	O
recognized	O
by	O
antibodies	B-protein
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	B-protein
antigenic	I-protein
region	I-protein
with	O
at	O
least	O
two	O
major	O
nonoverlapping	B-protein
epitopes	I-protein
.	O

Anti-	O
HBx	B-protein
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	B-protein
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	B-protein
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

JourNAL	NULL
oF	NULL
ViroLOGY	NULL
,	NULL
June	NULL
1990	NULL
,	NULL
p.	NULL
2802-2809	NULL
0022-538	NULL
X	NULL
,	NULL
/90/062802-08	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Mapping	NULL
of	NULL
B-Cell	NULL
Epitopes	NULL
of	NULL
the	NULL
Human	NULL
Hepatitis	NULL
B	NULL
Virus	NULL
X	NULL
Protein	NULL
MARIETTA	NULL
STEMLER	NULL
,	NULL
'	NULL
THOMAS	NULL
WEIMER	NULL
,	NULL
'	NULL
ZHEN-XING	NULL
TU	NULL
,	NULL
``	NULL
DA-FANG	NULL
WAN	NULL
,	NULL
'	NULL
#	NULL
MASSIMO	NULL
LEVRERO	NULL
,	NULL
``	NULL
CHRISTINA	NULL
JUNG	NULL
,	NULL
``	NULL
GERD	NULL
R.	NULL
PAPE	NULL
,	NULL
``	NULL
anp	NULL
HANS	NULL
WILL'*	NULL
Max-Planck-Institut	NULL
fiir	NULL
Biochemie	NULL
,	NULL
Am	NULL
Klopferspitz	NULL
18a	NULL
,	NULL
8033	NULL
Martinsried	NULL
,	NULL
Munich	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
;	NULL
Clinica	NULL
Medica	NULL
,	NULL
Universita	NULL
di	NULL
Roma	NULL
``	NULL
La	NULL
Sapienza	NULL
,	NULL
``	NULL
00161	NULL
Rome	NULL
,	NULL
Italy	NULL
;	NULL
and	NULL
Institut	NULL
fiir	NULL
Immunologie	NULL
,	NULL
8000	NULL
Munich	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
Received	NULL
2	NULL
January	NULL
1990/Accepted	NULL
26	NULL
February	NULL
1990	NULL
The	NULL
immune	NULL
response	NULL
to	NULL
the	NULL
X	NULL
protein	NULL
of	NULL
human	NULL
hepatitis	NULL
B	NULL
virus	NULL
(	NULL
HBV	NULL
)	NULL
was	NULL
studied	NULL
by	NULL
epitope	NULL
mapping	NULL
by	NULL
using	NULL
a	NULL
set	NULL
of	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
and	NULL
synthetic	NULL
peptides	NULL
.	NULL

Antibodies	NULL
in	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
and	NULL
chronic	NULL
HBV	NULL
infection	NULL
showed	NULL
a	NULL
multispecific	NULL
immune	NULL
response	NULL
.	NULL

Each	NULL
serum	NULL
contained	NULL
antibodies	NULL
to	NULL
a	NULL
different	NULL
set	NULL
of	NULL
epitopes	NULL
,	NULL
which	NULL
taken	NULL
together	NULL
cover	NULL
most	NULL
of	NULL
the	NULL
HBx	NULL
sequence	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
epitopes	NULL
were	NULL
detectable	NULL
only	NULL
by	NULL
immunoblotting	NULL
with	NULL
fusion	NULL
proteins	NULL
;	NULL
others	NULL
were	NULL
detectable	NULL
only	NULL
by	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
with	NULL
synthetic	NULL
peptides	NULL
.	NULL

The	NULL
carboxy-terminal	NULL
half	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
was	NULL
preferentially	NULL
recognized	NULL
by	NULL
antibodies	NULL
from	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
and	NULL
contained	NULL
a	NULL
short	NULL
immunodominant	NULL
antigenic	NULL
region	NULL
with	NULL
at	NULL
least	NULL
two	NULL
major	NULL
nonoverlapping	NULL
epitopes	NULL
.	NULL

Anti-HBx	NULL
antibody	NULL
titers	NULL
as	NULL
revealed	NULL
by	NULL
peptide	NULL
ELISAs	NULL
were	NULL
highest	NULL
and	NULL
most	NULL
frequent	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
and	NULL
usually	NULL
low	NULL
in	NULL
acutely	NULL
infected	NULL
patients	NULL
and	NULL
asymptomatic	NULL
carriers	NULL
.	NULL

The	NULL
data	NULL
demonstrate	NULL
a	NULL
remarkable	NULL
qualitative	NULL
and	NULL
quantitative	NULL
heterogeneity	NULL
of	NULL
the	NULL
humoral	NULL
HBx	NULL
immune	NULL
response	NULL
which	NULL
can	NULL
be	NULL
monitored	NULL
by	NULL
HBx-specific	NULL
peptide	NULL
ELISAs	NULL
.	NULL

Such	NULL
tests	NULL
may	NULL
become	NULL
useful	NULL
diagnostic	NULL
tools	NULL
.	NULL

Hepatitis	NULL
B	NULL
viruses	NULL
(	NULL
HBVs	NULL
)	NULL
have	NULL
been	NULL
found	NULL
in	NULL
humans	NULL
and	NULL
several	NULL
animal	NULL
species	NULL
such	NULL
as	NULL
woodchucks	NULL
,	NULL
ground	NULL
squirrels	NULL
,	NULL
Pekin	NULL
ducks	NULL
,	NULL
and	NULL
grey	NULL
herons	NULL
(	NULL
14	NULL
,	NULL
41	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Infection	NULL
with	NULL
these	NULL
viruses	NULL
often	NULL
leads	NULL
to	NULL
acute	NULL
or	NULL
chronic	NULL
infection	NULL
and	NULL
various	NULL
forms	NULL
of	NULL
liver	NULL
diseases	NULL
,	NULL
but	NULL
it	NULL
may	NULL
also	NULL
lead	NULL
to	NULL
an	NULL
asymptomatic	NULL
chronic	NULL
carrier	NULL
state	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
7	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
chronic	NULL
infection	NULL
with	NULL
mamma-lian	NULL
,	NULL
but	NULL
not	NULL
avian	NULL
,	NULL
HBVs	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
high	NULL
risk	NULL
for	NULL
development	NULL
of	NULL
hepatocellular	NULL
carcinoma	NULL
(	NULL
HCC	NULL
)	NULL
(	NULL
1	NULL
,	NULL
41	NULL
)	NULL
.	NULL

HBV	NULL
s	NULL
are	NULL
not	NULL
cytopathogenic	NULL
,	NULL
and	NULL
therefore	NULL
it	NULL
is	NULL
generally	NULL
assumed	NULL
that	NULL
viral	NULL
hepatitis	NULL
is	NULL
mediated	NULL
primarily	NULL
by	NULL
immune	NULL
defense	NULL
mechanisms	NULL
.	NULL

The	NULL
immune	NULL
response	NULL
has	NULL
been	NULL
studied	NULL
in	NULL
the	NULL
most	NULL
detail	NULL
for	NULL
virus	NULL
components	NULL
expressed	NULL
in	NULL
large	NULL
amounts	NULL
.	NULL

B-	NULL
and	NULL
T-cell	NULL
epitopes	NULL
have	NULL
been	NULL
identified	NULL
for	NULL
two	NULL
antigens	NULL
encoded	NULL
by	NULL
the	NULL
viral	NULL
C	NULL
gene	NULL
,	NULL
the	NULL
major	NULL
nucleocapsid	NULL
protein	NULL
(	NULL
HBcAg	NULL
)	NULL
,	NULL
and	NULL
the	NULL
e	NULL
antigen	NULL
(	NULL
HBeAg	NULL
)	NULL
(	NULL
27	NULL
,	NULL
28	NULL
,	NULL
39	NULL
)	NULL
,	NULL
a	NULL
protein	NULL
which	NULL
is	NULL
secreted	NULL
into	NULL
the	NULL
serum	NULL
and	NULL
which	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
viral	NULL
particles	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Circumstantial	NULL
evidence	NULL
suggests	NULL
an	NULL
important	NULL
role	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
these	NULL
antigens	NULL
in	NULL
terms	NULL
of	NULL
virus	NULL
elimination	NULL
and	NULL
pathogenicity	NULL
,	NULL
and	NULL
antibodies	NULL
to	NULL
both	NULL
antigens	NULL
are	NULL
early	NULL
diagnostic	NULL
markers	NULL
of	NULL
HBV	NULL
infection	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Similar	NULL
studies	NULL
have	NULL
been	NULL
performed	NULL
on	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
the	NULL
three	NULL
envelope	NULL
proteins	NULL
,	NULL
pre-S1	NULL
,	NULL
pre-S2	NULL
,	NULL
and	NULL
HBsAg	NULL
.	NULL

B-	NULL
and	NULL
T-cell	NULL
epitopes	NULL
have	NULL
been	NULL
mapped	NULL
,	NULL
and	NULL
the	NULL
participation	NULL
of	NULL
antibodies	NULL
and	NULL
T	NULL
cells	NULL
to	NULL
envelope	NULL
epitopes	NULL
in	NULL
immune-mediated	NULL
defense	NULL
mechanisms	NULL
and	NULL
the	NULL
use	NULL
of	NULL
envelope	NULL
proteins	NULL
as	NULL
vaccines	NULL
have	NULL
been	NULL
extensively	NULL
investigated	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
minor	NULL
viral	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
the	NULL
viral	NULL
polymerase	NULL
and	NULL
genome-linked	NULL
protein	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

t	NULL
Present	NULL
address	NULL
:	NULL
Institute	NULL
for	NULL
Hepatobiliary	NULL
Surgery	NULL
,	NULL
Shanghai	NULL
,	NULL
People	NULL
's	NULL
Republic	NULL
of	NULL
China	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
Shanghai	NULL
Cancer	NULL
Institute	NULL
,	NULL
Shanghai	NULL
200032	NULL
,	NULL
People	NULL
's	NULL
Republic	NULL
of	NULL
China	NULL
.	NULL

2802	NULL
(	NULL
collectively	NULL
designated	NULL
herein	NULL
as	NULL
P	NULL
proteins	NULL
)	NULL
,	NULL
and	NULL
a	NULL
viral	NULL
protein	NULL
with	NULL
a	NULL
transcriptional	NULL
transactivator	NULL
function	NULL
,	NULL
designated	NULL
HBx	NULL
,	NULL
have	NULL
been	NULL
less	NULL
well	NULL
studied	NULL
.	NULL

In	NULL
several	NULL
reports	NULL
,	NULL
antibodies	NULL
to	NULL
P	NULL
gene-encoded	NULL
proteins	NULL
were	NULL
identified	NULL
in	NULL
human	NULL
patient	NULL
sera	NULL
(	NULL
3	NULL
,	NULL
10	NULL
,	NULL
46	NULL
,	NULL
50a	NULL
)	NULL
.	NULL

So	NULL
far	NULL
,	NULL
a	NULL
T-cell	NULL
immune	NULL
response	NULL
to	NULL
P	NULL
proteins	NULL
has	NULL
not	NULL
been	NULL
described	NULL
.	NULL

The	NULL
HBx	NULL
protein	NULL
is	NULL
currently	NULL
one	NULL
of	NULL
the	NULL
most	NULL
intensively	NULL
studied	NULL
HBV	NULL
proteins	NULL
.	NULL

Its	NULL
function	NULL
in	NULL
vitro	NULL
as	NULL
a	NULL
transcriptional	NULL
transactivator	NULL
of	NULL
HBV	NULL
or	NULL
heterologous	NULL
promoters	NULL
invited	NULL
speculations	NULL
on	NULL
its	NULL
possible	NULL
role	NULL
in	NULL
vivo	NULL
in	NULL
hepadna-virus	NULL
biology	NULL
and	NULL
pathogenicity	NULL
(	NULL
5	NULL
,	NULL
42	NULL
,	NULL
44	NULL
,	NULL
47	NULL
,	NULL
48	NULL
,	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

It	NULL
is	NULL
,	NULL
however	NULL
,	NULL
not	NULL
yet	NULL
clear	NULL
whether	NULL
HBx	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
virus	NULL
life	NULL
cycle	NULL
.	NULL

The	NULL
X	NULL
gene	NULL
is	NULL
present	NULL
only	NULL
in	NULL
mammalian	NULL
hepadnaviruses	NULL
and	NULL
is	NULL
moderately	NULL
conserved	NULL
in	NULL
sequence	NULL
(	NULL
23	NULL
,	NULL
41	NULL
)	NULL
.	NULL

The	NULL
HBx	NULL
protein	NULL
has	NULL
been	NULL
expressed	NULL
successfully	NULL
in	NULL
several	NULL
in	NULL
vitro	NULL
expression	NULL
systems	NULL
using	NULL
cultured	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
20	NULL
,	NULL
21a	NULL
,	NULL
31	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
43	NULL
)	NULL
.	NULL

The	NULL
first	NULL
indirect	NULL
evidence	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
in	NULL
vivo	NULL
was	NULL
the	NULL
demonstration	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
some	NULL
sera	NULL
of	NULL
infected	NULL
patients	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Some	NULL
reports	NULL
suggested	NULL
preferential	NULL
induction	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
patients	NULL
with	NULL
hepatocellular	NULL
carcinoma	NULL
(	NULL
31	NULL
,	NULL
36	NULL
)	NULL
;	NULL
others	NULL
found	NULL
a	NULL
low	NULL
incidence	NULL
in	NULL
HCC	NULL
patients	NULL
and	NULL
more	NULL
frequent	NULL
,	NULL
high	NULL
titers	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
HBV	NULL
infection	NULL
(	NULL
9	NULL
,	NULL
16	NULL
,	NULL
2la	NULL
,	NULL
22	NULL
,	NULL
26	NULL
,	NULL
35	NULL
)	NULL
.	NULL

It	NULL
is	NULL
an	NULL
open	NULL
question	NULL
whether	NULL
the	NULL
different	NULL
antigens	NULL
and	NULL
antisera	NULL
,	NULL
sequence	NULL
vari-ants	NULL
,	NULL
or	NULL
the	NULL
different	NULL
techniques	NULL
used	NULL
are	NULL
responsible	NULL
for	NULL
these	NULL
conflicting	NULL
results	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
detailed	NULL
analysis	NULL
of	NULL
the	NULL
humoral	NULL
immune	NULL
response	NULL
to	NULL
HBx	NULL
in	NULL
human	NULL
patients	NULL
.	NULL

By	NULL
epitope	NULL
mapping	NULL
,	NULL
we	NULL
tried	NULL
to	NULL
answer	NULL
the	NULL
following	NULL
questions	NULL
.	NULL

First	NULL
,	NULL
are	NULL
there	NULL
major	NULL
antigenic	NULL
regions	NULL
recognized	NULL
by	NULL
the	NULL
majority	NULL
of	NULL
anti-HBx-positive	NULL
human	NULL
sera	NULL
?	NULL

Second	NULL
,	NULL
is	NULL
the	NULL
immune	NULL
response	NULL
to	NULL
individual	NULL
HBx	NULL
epitopes	NULL
correlated	NULL
with	NULL
the	NULL
type	NULL
of	NULL
liver	NULL
disease	NULL
of	NULL
the	NULL
infected	NULL
patient	NULL
?	NULL

And	NULL
,	NULL
third	NULL
,	NULL
is	NULL
it	NULL
possible	NULL
to	NULL
design	NULL
HBx	NULL
epitope-specific	NULL
enzyme-linked	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
immunosorbent	NULL
assays	NULL
(	NULL
ELISAs	NULL
)	NULL
to	NULL
monitor	NULL
the	NULL
anti-HBx	NULL
antibody	NULL
response	NULL
in	NULL
clinical	NULL
routine	NULL
settings	NULL
?	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Sera	NULL
.	NULL

Sera	NULL
of	NULL
HBV	NULL
-infected	NULL
patients	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Policlinico	NULL
Umberto	NULL
I	NULL
,	NULL
Rome	NULL
,	NULL
Italy	NULL
,	NULL
and	NULL
GroBklinikum	NULL
GroBhadern	NULL
,	NULL
Munich	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
.	NULL

Blood	NULL
samples	NULL
negative	NULL
for	NULL
HBV	NULL
markers	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Blood	NULL
Transfusion	NULL
Service	NULL
,	NULL
Public	NULL
Health	NULL
Department	NULL
,	NULL
Munich	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
.	NULL

Classical	NULL
serological	NULL
markers	NULL
of	NULL
HBV	NULL
infection	NULL
such	NULL
as	NULL
HBsAg	NULL
,	NULL
anti-HBs	NULL
,	NULL
anti-HBc	NULL
,	NULL
HBeAg	NULL
,	NULL
and	NULL
anti-HBe	NULL
were	NULL
determined	NULL
by	NULL
commercial	NULL
assays	NULL
(	NULL
Abbott	NULL
Laboratories	NULL
,	NULL
North	NULL
Chicago	NULL
,	NULL
III	NULL
.	NULL
)	NULL

.	NULL

Synthetic	NULL
HBx	NULL
peptides	NULL
.	NULL

Fifteen	NULL
chemically	NULL
synthesized	NULL
peptides	NULL
covering	NULL
the	NULL
whole	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
HBV	NULL
X	NULL
gene	NULL
(	NULL
subtype	NULL
ayw	NULL
[	NULL
13	NULL
]	NULL
)	NULL
were	NULL
used	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

They	NULL
were	NULL
more	NULL
than	NULL
90	NULL
%	NULL
pure	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
high-pressure	NULL
liquid	NULL
chromatography	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Construction	NULL
of	NULL
plasmids	NULL
for	NULL
expression	NULL
of	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
.	NULL

All	NULL
constructions	NULL
were	NULL
made	NULL
by	NULL
using	NULL
conventional	NULL
cloning	NULL
procedures	NULL
(	NULL
24	NULL
)	NULL
.	NULL

DNA	NULL
fragments	NULL
containing	NULL
either	NULL
the	NULL
whole	NULL
X	NULL
gene	NULL
or	NULL
parts	NULL
of	NULL
it	NULL
were	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
2136	NULL
cells	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
vectors	NULL
used	NULL
(	NULL
pEx	NULL
4la	NULL
,	NULL
pEx	NULL
41b	NULL
,	NULL
and	NULL
pEx	NULL
41¢	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
are	NULL
derivatives	NULL
of	NULL
plasmid	NULL
pPLc	NULL
24	NULL
(	NULL
38	NULL
)	NULL
modified	NULL
by	NULL
insertion	NULL
of	NULL
versatile	NULL
polylinkers	NULL
(	NULL
T.	NULL
Weimer	NULL
,	NULL
Ph.D.	NULL
thesis	NULL
,	NULL
Ludwig-Maximilians-Universitat	NULL
,	NULL
Munich	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

For	NULL
expression	NULL
of	NULL
the	NULL
full-length	NULL
HBx	NULL
protein	NULL
,	NULL
an	NULL
HBV	NULL
fragment	NULL
containing	NULL
the	NULL
X	NULL
gene	NULL
coding	NULL
region	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
cloned	NULL
HBV	NULL
DNA	NULL
(	NULL
13	NULL
)	NULL
by	NULL
restriction	NULL
enzyme	NULL
digestion	NULL
with	NULL
Ncol	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
Bgilll	NULL
(	NULL
cleavage	NULL
site	NULL
within	NULL
the	NULL
C	NULL
gene	NULL
)	NULL
,	NULL
separation	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
purification	NULL
by	NULL
electroelution	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
ligated	NULL
to	NULL
vector	NULL
pEx	NULL
4la	NULL
.	NULL

For	NULL
expression	NULL
of	NULL
truncated	NULL
HBx	NULL
protein	NULL
sequences	NULL
,	NULL
subfragments	NULL
of	NULL
the	NULL
X	NULL
gene	NULL
obtained	NULL
by	NULL
restriction	NULL
digestion	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
restriction	NULL
enzyme	NULL
and	NULL
BAL	NULL
31	NULL
digestion	NULL
were	NULL
cloned	NULL
into	NULL
vectors	NULL
pEx	NULL
4la	NULL
,	NULL
pEx	NULL
41b	NULL
,	NULL
or	NULL
pEx	NULL
41c	NULL
,	NULL
or	NULL
into	NULL
vector	NULL
pPLc	NULL
24	NULL
.	NULL

All	NULL
fragments	NULL
obtained	NULL
by	NULL
BAL	NULL
31	NULL
digestion	NULL
contained	NULL
a	NULL
HindIII	NULL
restriction	NULL
enzyme	NULL
recognition	NULL
site	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
which	NULL
is	NULL
derived	NULL
from	NULL
the	NULL
linker	NULL
region	NULL
of	NULL
the	NULL
pSP64	NULL
vector	NULL
into	NULL
which	NULL
the	NULL
HBV	NULL
DNA	NULL
was	NULL
previously	NULL
cloned	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Correct	NULL
insertion	NULL
was	NULL
assessed	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
(	NULL
40	NULL
)	NULL
of	NULL
the	NULL
virus-plasmid	NULL
junction	NULL
by	NULL
using	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
as	NULL
primer	NULL
.	NULL

Expression	NULL
of	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
in	NULL
E.	NULL
coli	NULL
.	NULL

The	NULL
expression	NULL
plasmids	NULL
contain	NULL
a	NULL
heat-inducible	NULL
leftward	NULL
lambda	NULL
promoter	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Bacteria	NULL
were	NULL
grown	NULL
overnight	NULL
in	NULL
Standard	NULL
I	NULL
medium	NULL
(	NULL
E.	NULL
Merck	NULL
AG	NULL
,	NULL
Darmstadt	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
containing	NULL
100	NULL
ug	NULL
of	NULL
ampicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
for	NULL
induction	NULL
of	NULL
protein	NULL
expression	NULL
,	NULL
the	NULL
overnight	NULL
culture	NULL
was	NULL
diluted	NULL
1:4	NULL
with	NULL
prewarmed	NULL
medium	NULL
(	NULL
42°C	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
2	NULL
to	NULL
3	NULL
h	NULL
at	NULL
42°C	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
cloned	NULL
HBV	NULL
fragments	NULL
resulted	NULL
in	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
containing	NULL
at	NULL
their	NULL
amino	NULL
termini	NULL
99	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
replicase	NULL
protein	NULL
of	NULL
bacteriophage	NULL
MS2	NULL
and	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
additional	NULL
amino	NULL
acids	NULL
derived	NULL
from	NULL
linker	NULL
and	NULL
from	NULL
plasmid	NULL
pBR	NULL
sequences	NULL
(	NULL
24	NULL
,	NULL
61	NULL
,	NULL
or	NULL
66	NULL
amino	NULL
acids	NULL
)	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
.	NULL

For	NULL
immunoblotting	NULL
with	NULL
recombinant	NULL
proteins	NULL
,	NULL
a	NULL
protein	NULL
extract	NULL
was	NULL
prepared	NULL
by	NULL
boiling	NULL
the	NULL
bacteria	NULL
in	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
sample	NULL
buffer	NULL
(	NULL
cells	NULL
from	NULL
a	NULL
1-ml	NULL
culture	NULL
in	NULL
0.3	NULL
ml	NULL
of	NULL
buffer	NULL
)	NULL
(	NULL
50a	NULL
)	NULL
.	NULL

The	NULL
proteins	NULL
of	NULL
20	NULL
ul	NULL
of	NULL
these	NULL
extracts	NULL
were	NULL
separated	NULL
by	NULL
SDS-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
(	NULL
21	NULL
)	NULL
and	NULL
immunoblotted	NULL
ANTIGENICITY	NULL
OF	NULL
HEPATITIS	NULL
B	NULL
VIRUS	NULL
X	NULL
PROTEIN	NULL
2803	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
filters	NULL
,	NULL
incubated	NULL
overnight	NULL
in	NULL
phos-phate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
(	NULL
8	NULL
mM	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
and	NULL
140	NULL
mM	NULL
NaCl	NULL
)	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
to	NULL
abolish	NULL
unspecific	NULL
reactivity	NULL
,	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
human	NULL
sera	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:1,000	NULL
in	NULL
PBS-1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
PBS-0Q.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

Bound	NULL
human	NULL
antibodies	NULL
were	NULL
visualized	NULL
by	NULL
autoradiogra-phy	NULL
after	NULL
incubation	NULL
of	NULL
the	NULL
filters	NULL
for	NULL
60	NULL
min	NULL
with	NULL
2	NULL
wCi	NULL
of	NULL
iodinated	NULL
protein	NULL
A	NULL
(	NULL
30	NULL
mCi/mg	NULL
;	NULL
Amersham	NULL
Buchler	NULL
,	NULL
Braun-schweig	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
25	NULL
ml	NULL
of	NULL
PBS-1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
washing	NULL
several	NULL
times	NULL
with	NULL
PBS-0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
and	NULL
extensive	NULL
washing	NULL
with	NULL
water	NULL
.	NULL

ELISAs	NULL
with	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
.	NULL

Microdilution	NULL
plates	NULL
were	NULL
coated	NULL
with	NULL
HBx	NULL
peptides	NULL
or	NULL
with	NULL
an	NULL
unrelated	NULL
control	NULL
peptide	NULL
(	NULL
amino	NULL
acid	NULL
sequence	NULL
TTESKLRREFEVYG	NULL
PIKRIH	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
ug	NULL
per	NULL
well	NULL
in	NULL
E-PBS	NULL
(	NULL
10	NULL
mM	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
KH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
170	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
3	NULL
mM	NULL
KCI	NULL
[	NULL
pH	NULL
7.41	NULL
)	NULL
for	NULL
2	NULL
h.	NULL
Unbound	NULL
peptide	NULL
was	NULL
removed	NULL
by	NULL
washing	NULL
several	NULL
times	NULL
with	NULL
E-PBS-5	NULL
%	NULL
Tween	NULL
20	NULL
.	NULL

Unspecific	NULL
binding	NULL
sites	NULL
were	NULL
blocked	NULL
by	NULL
incubation	NULL
with	NULL
E-PBS-5	NULL
%	NULL
Tween	NULL
20	NULL
at	NULL
4°C	NULL
overnight	NULL
.	NULL

Human	NULL
sera	NULL
diluted	NULL
1:100	NULL
in	NULL
E-PBS-5	NULL
%	NULL
Tween	NULL
20	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
,	NULL
and	NULL
then	NULL
the	NULL
microdilution	NULL
plate	NULL
was	NULL
washed	NULL
several	NULL
times	NULL
with	NULL
E-PBS-5	NULL
%	NULL
Tween	NULL
20	NULL
.	NULL

Bound	NULL
antibodies	NULL
were	NULL
detected	NULL
with	NULL
goat	NULL
anti-human	NULL
antibodies	NULL
coupled	NULL
to	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
antibody	NULL
dilution	NULL
,	NULL
1:3,000	NULL
)	NULL
.	NULL

After	NULL
development	NULL
with	NULL
substrate	NULL
solution	NULL
(	NULL
0.5	NULL
mg	NULL
of	NULL
o-phenylenediamine	NULL
per	NULL
ml	NULL
in	NULL
0.1	NULL
M	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
-0.05	NULL
M	NULL
citric	NULL
acid	NULL
,	NULL
pH	NULL
6.0	NULL
,	NULL
and	NULL
0.5	NULL
wl	NULL
of	NULL
H,0	NULL
;	NULL
,	NULL
per	NULL
ml	NULL
)	NULL
,	NULL
the	NULL
optical	NULL
density	NULL
was	NULL
measured	NULL
at	NULL
492	NULL
nm	NULL
.	NULL

All	NULL
tests	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
duplicates	NULL
.	NULL

Competitive	NULL
inhibition	NULL
assays	NULL
with	NULL
HBx	NULL
peptides	NULL
.	NULL

For	NULL
these	NULL
assays	NULL
,	NULL
sera	NULL
diluted	NULL
1:3,000	NULL
with	NULL
PBS-1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
were	NULL
incubated	NULL
with	NULL
HBx	NULL
peptides	NULL
(	NULL
5	NULL
ug	NULL
of	NULL
each	NULL
peptide	NULL
per	NULL
pl	NULL
of	NULL
serum	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
1	NULL
ml	NULL
for	NULL
2	NULL
h	NULL
at	NULL
28°C	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
then	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
the	NULL
nitrocellulose	NULL
filter	NULL
containing	NULL
the	NULL
immobilized	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
,	NULL
and	NULL
unbound	NULL
antibodies	NULL
were	NULL
removed	NULL
by	NULL
washing	NULL
several	NULL
times	NULL
with	NULL
PBS-0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

The	NULL
bound	NULL
antibodies	NULL
were	NULL
detected	NULL
as	NULL
described	NULL
above	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
in	NULL
£	NULL
.	NULL

coli	NULL
.	NULL

One	NULL
type	NULL
of	NULL
substrate	NULL
used	NULL
for	NULL
epitope	NULL
mapping	NULL
was	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
.	NULL

They	NULL
were	NULL
obtained	NULL
by	NULL
cloning	NULL
of	NULL
the	NULL
complete	NULL
X	NULL
gene	NULL
or	NULL
X	NULL
gene	NULL
fragments	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
into	NULL
procaryotic	NULL
expression	NULL
vectors	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
efficiency	NULL
in	NULL
E.	NULL
coli	NULL
was	NULL
assessed	NULL
by	NULL
analyzing	NULL
proteins	NULL
of	NULL
whole-cell	NULL
extracts	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
Coomassie	NULL
brilliant	NULL
blue	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
or	NULL
immunoblotting	NULL
with	NULL
an	NULL
anti-MS2	NULL
monoclonal	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

With	NULL
one	NULL
exception	NULL
(	NULL
clone	NULL
5	NULL
)	NULL
,	NULL
all	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
were	NULL
efficiently	NULL
expressed	NULL
(	NULL
1	NULL
to	NULL
5	NULL
%	NULL
of	NULL
the	NULL
total	NULL
E.	NULL
coli	NULL
proteins	NULL
;	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
MS2-HBx	NULL
fusion	NULL
protein	NULL
of	NULL
clone	NULL
5	NULL
was	NULL
low	NULL
,	NULL
but	NULL
it	NULL
could	NULL
easily	NULL
be	NULL
visualized	NULL
by	NULL
immunoblotting	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
to	NULL
MS2	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
or	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
HBx	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
fusion	NULL
proteins	NULL
was	NULL
in	NULL
close	NULL
agreement	NULL
with	NULL
that	NULL
predicted	NULL
from	NULL
the	NULL
constructions	NULL
.	NULL

Minor	NULL
fusion	NULL
proteins	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
Coomassie	NULL
brilliant	NULL
blue	NULL
staining	NULL
and	NULL
immunoblotting	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
and	NULL
D	NULL
)	NULL
,	NULL
which	NULL
are	NULL
smaller	NULL
in	NULL
size	NULL
than	NULL
predicted	NULL
,	NULL
probably	NULL
represent	NULL
degradation	NULL
products	NULL
or	NULL
may	NULL
derive	NULL
from	NULL
premature	NULL
termination	NULL
of	NULL
translation	NULL
.	NULL

2804	NULL
STEMLER	NULL
ET	NULL
AL	NULL
.	NULL

Bam	NULL
BI	NULL
Aval	NULL
NeoL	NULL
i	NULL
Bst	NULL
UI	NULL
l	NULL
HpaII	NULL
SspI	NULL
Dral	NULL
FspI	NULL
U	NULL
+	NULL
+	NULL
t	NULL
t	NULL
2656	NULL
§o	NULL
»	NULL
-	NULL
3117	NULL
1	NULL
1	NULL
2	NULL
2	NULL
3	NULL
inners	NULL
3	NULL
*	NULL
a	NULL
5	NULL
wea	NULL
5	NULL
6	NULL
6	NULL
7	NULL
wanes	NULL
7	NULL
8	NULL
wae	NULL
___	NULL
8	NULL
9	NULL
9	NULL
10	NULL
10	NULL
eom	NULL
wom	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
16	NULL
17	NULL
J.	NULL
Viror	NULL
.	NULL

Hucleotide	NULL
Amino	NULL
acide	NULL
HBx	NULL
position	NULL
positions	NULL
[	NULL
length	NULL
peptides	NULL
2656	NULL
-	NULL
-	NULL
84	NULL
1	NULL
~	NULL
ise	NULL
|	NULL
is	NULL
Pi-1s	NULL
2656	NULL
-	NULL
2691	NULL
i-	NULL
ar	NULL
|	NULL
ir	NULL
P1	NULL
2656	NULL
-	NULL
2052	NULL
1	NULL
-	NULL
67	NULL
67	NULL
P1-6	NULL
,	NULL
P7	NULL
2656	NULL
~	NULL
2918	NULL
1	NULL
-	NULL
se	NULL
as	NULL
P1-8,99	NULL
2682	NULL
-	NULL
2745	NULL
|	NULL
10	NULL
-	NULL
32	NULL
22	NULL
P1	NULL
,	NULL
92	NULL
,	NULL
P3	NULL
2719	NULL
-	NULL
2918	NULL
|	NULL
22	NULL
-	NULL
ss	NULL
se	NULL
P2,03-8	NULL
,	NULL
P9	NULL
2750	NULL
-	NULL
zor8	NULL
|	NULL
35	NULL
-	NULL
ss	NULL
53	NULL
PA-8	NULL
,	NULL
P3	NULL
2804	NULL
-	NULL
2918	NULL
|	NULL
si	NULL
-	NULL
ss	NULL
37	NULL
PS	NULL
,	NULL
P6~8	NULL
,	NULL
P9	NULL
2062	NULL
-	NULL
2918	NULL
|	NULL
70	NULL
-	NULL
ss	NULL
18	NULL
P7	NULL
,	NULL
PB	NULL
,	NULL
P9	NULL
2062	NULL
-	NULL
3084	NULL
70	NULL
-	NULL
143	NULL
73	NULL
P7	NULL
,	NULL
2892	NULL
-	NULL
3006	NULL
|	NULL
so	NULL
-	NULL
117	NULL
37	NULL
P8	NULL
,	NULL
B9-11	NULL
,	NULL
P12	NULL
2922	NULL
-	NULL
3084	NULL
so	NULL
-	NULL
143	NULL
53	NULL
P9	NULL
,	NULL
PLO-13	NULL
,	NULL
P14-15	NULL
2960	NULL
-	NULL
3084	NULL
|103	NULL
-	NULL
143	NULL
«	NULL
0	NULL
P10	NULL
,	NULL
PL1-13	NULL
,	NULL
14-15	NULL
3012	NULL
-	NULL
3084	NULL
{	NULL
120	NULL
-	NULL
143	NULL
23	NULL
P12,913	NULL
,	NULL
P14-15	NULL
3012	NULL
-	NULL
-	NULL
64	NULL
120	NULL
-	NULL
154	NULL
34	NULL
P12	NULL
,	NULL
913-15	NULL
sore	NULL
-	NULL
e4	NULL
[	NULL
139	NULL
-	NULL
154	NULL
15	NULL
P14	NULL
,	NULL
R15	NULL
soss	NULL
-	NULL
se	NULL
{	NULL
144	NULL
-	NULL
154	NULL
10	NULL
P14	NULL
P15	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

HBx	NULL
polypeptides	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
and	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
used	NULL
for	NULL
ELISAs	NULL
and	NULL
in	NULL
competition	NULL
experiments	NULL
.	NULL

The	NULL
thick	NULL
,	NULL
hatched	NULL
horizontal	NULL
arrow	NULL
indicates	NULL
the	NULL
HBV	NULL
X	NULL
gene	NULL
.	NULL

Some	NULL
restriction	NULL
sites	NULL
used	NULL
for	NULL
molecular	NULL
cloning	NULL
are	NULL
shown	NULL
by	NULL
vertical	NULL
arrows	NULL
.	NULL

Lines	NULL
below	NULL
the	NULL
X	NULL
gene	NULL
indicate	NULL
X	NULL
gene	NULL
sequences	NULL
expressed	NULL
as	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
.	NULL

Nucleotide	NULL
positions	NULL
of	NULL
the	NULL
cloned	NULL
HBV	NULL
DNA	NULL
fragments	NULL
are	NULL
as	NULL
described	NULL
by	NULL
Pasek	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
amino	NULL
acid	NULL
positions	NULL
of	NULL
the	NULL
HBx	NULL
sequences	NULL
expressed	NULL
as	NULL
fusion	NULL
proteins	NULL
are	NULL
indicated	NULL
,	NULL
and	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
are	NULL
shown	NULL
as	NULL
embedded	NULL
totally	NULL
(	NULL
bold	NULL
)	NULL
or	NULL
in	NULL
part	NULL
(	NULL
plain	NULL
)	NULL
in	NULL
the	NULL
HBx	NULL
fusion	NULL
protein	NULL
sequences	NULL
.	NULL

a	NULL
:	NULL
G	NULL
I1	NULL
G	NULL
T	NULL
M	NULL
D	NULL
P	NULL
G	NULL
S	NULL
Ss	NULL
§	NULL
L	NULL
D	NULL
b	NULL
:	NULL
E	NULL
L	NULL
Y	NULL
P	NULL
W	NULL
I	NULL
P	NULL
@	NULL
a	NULL
Q	NULL
a	NULL
w	NULL
C.	NULL
N	NULL
W	NULL
Y	NULL
H	NULL
G	NULL
S	NULL
$	NULL
R	NULL
E	NULL
L	NULL
K	NULL
L	NULL
G	NULL
Y	NULL
R	NULL
C	NULL
|	NULL
«	NULL
BDG	NULL
_L	NULL
GGGAATTGGTACCATGGATCCCGSGAGCTCAAGCTTGGATATCGATGCATCGAATTCTGCAGATCTCGAGCTT	NULL
I	NULL
D	NULL
A	NULL
S	NULL
N	NULL
S	NULL
$	NULL
a	NULL
D	NULL
L	NULL
E	NULL
i	NULL
I1	NULL
S	NULL
$	NULL
M	NULL
H	NULL
R	NULL
|	NULL
L	NULL
Q	NULL
|	NULL
S	NULL
S	NULL
E	NULL
F	NULL
C	NULL
R	NULL
S	NULL
R	NULL
A	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Map	NULL
of	NULL
expression	NULL
vectors	NULL
pEx	NULL
41a	NULL
,	NULL
pEx	NULL
41b	NULL
,	NULL
and	NULL
pEx	NULL
41c	NULL
.	NULL

HBV	NULL
fragments	NULL
were	NULL
inserted	NULL
in	NULL
different	NULL
cloning	NULL
sites	NULL
of	NULL
the	NULL
linker	NULL
region	NULL
downstream	NULL
of	NULL
the	NULL
MS2	NULL
gene	NULL
sequences	NULL
.	NULL

Amino	NULL
acid	NULL
sequences	NULL
of	NULL
the	NULL
reading	NULL
frames	NULL
of	NULL
the	NULL
polylinker	NULL
region	NULL
of	NULL
vectors	NULL
pEx	NULL
41a	NULL
,	NULL
pEXx	NULL
41b	NULL
,	NULL
and	NULL
pEx	NULL
41¢c	NULL
are	NULL
given	NULL
in	NULL
the	NULL
single-letter	NULL
code	NULL
.	NULL

Abbreviations	NULL
:	NULL
MS2	NULL
POL	NULL
,	NULL
part	NULL
of	NULL
the	NULL
replicase	NULL
gene	NULL
of	NULL
bacteriophage	NULL
MS	NULL
?	NULL

;	NULL
lambda	NULL
PL	NULL
,	NULL
,	NULL
leftward	NULL
promoter	NULL
of	NULL
phage	NULL
lambda	NULL
;	NULL
amp	NULL
'	NULL
,	NULL
B-lactamase	NULL
gene	NULL
.	NULL

2	NULL
1	NULL
i	NULL
$	NULL
4.5	NULL
i	NULL
I	NULL
%	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
M	NULL
(	NULL
kd	NULL
)	NULL
ANTIGENICITY	NULL
OF	NULL
HEPATITIS	NULL
B	NULL
VIRUS	NULL
X	NULL
PROTEIN	NULL
2805	NULL
I	NULL
.	NULL

5	NULL
1	NULL
2	NULL
|	NULL
M	NULL
(	NULL
kd	NULL
)	NULL
-	NULL
94	NULL
D	NULL
-	NULL
30	NULL
-20	NULL
-	NULL
14	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
with	NULL
an	NULL
MS2-specific	NULL
monoclonal	NULL
mouse	NULL
antibody	NULL
and	NULL
anti-HBx	NULL
antibody-positive	NULL
human	NULL
sera	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Proteins	NULL
of	NULL
E.	NULL
coli	NULL
cell	NULL
extracts	NULL
,	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
stained	NULL
by	NULL
Coomassie	NULL
brillant	NULL
blue	NULL
.	NULL

(	NULL
B	NULL
to	NULL
F	NULL
)	NULL
Immunoblots	NULL
with	NULL
sera	NULL
of	NULL
a	NULL
chronic	NULL
HBV	NULL
carrier	NULL
(	NULL
HBsAg*	NULL
HBeAg*	NULL
HBV	NULL
DNA	NULL
*	NULL
)	NULL
(	NULL
B	NULL
)	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
HCC	NULL
(	NULL
HBsAg*	NULL
anti-HBet	NULL
DNA	NULL
*	NULL
)	NULL
(	NULL
C	NULL
)	NULL
,	NULL
a	NULL
mouse	NULL
anti-MS2	NULL
monoclonal	NULL
antibody	NULL
(	NULL
D	NULL
)	NULL
,	NULL
an	NULL
asymptomatic	NULL
HBV	NULL
carrier	NULL
(	NULL
HBsAg*	NULL
)	NULL
(	NULL
E	NULL
)	NULL
,	NULL
and	NULL
a	NULL
chronic	NULL
HBV	NULL
carrier	NULL
(	NULL
HBsAg*	NULL
HBeAg~	NULL
DNAT	NULL
)	NULL
(	NULL
F	NULL
)	NULL
.	NULL

Lane	NULL
numbers	NULL
refer	NULL
to	NULL
HBx	NULL
fusion	NULL
proteins	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
:	NULL
HCC	NULL
,	NULL
hepatocellular	NULL
carcinoma	NULL
;	NULL
M	NULL
,	NULL
molecular	NULL
weight	NULL
marker	NULL
;	NULL
kd	NULL
,	NULL
kilodalton	NULL
.	NULL

Epitope	NULL
mapping	NULL
by	NULL
immunoblotting	NULL
with	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
.	NULL

For	NULL
epitope	NULL
mapping	NULL
,	NULL
sera	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
or	NULL
chronic	NULL
hepatitis	NULL
or	NULL
HCC	NULL
and	NULL
from	NULL
asymptomatic	NULL
carriers	NULL
were	NULL
tested	NULL
by	NULL
immunoblotting	NULL
with	NULL
a	NULL
set	NULL
of	NULL
17	NULL
different	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

All	NULL
50	NULL
human	NULL
sera	NULL
used	NULL
in	NULL
this	NULL
study	NULL
had	NULL
been	NULL
previously	NULL
screened	NULL
for	NULL
anti-HBx	NULL
antibodies	NULL
by	NULL
immunoblotting	NULL
or	NULL
by	NULL
an	NULL
ELISA	NULL
with	NULL
full-length	NULL
MS2-HBx	NULL
fusion	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Four	NULL
different	NULL
reaction	NULL
patterns	NULL
were	NULL
obtained	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
anti-HBx	NULL
antibody-positive	NULL
sera	NULL
tested	NULL
(	NULL
43	NULL
of	NULL
50	NULL
)	NULL
reacted	NULL
very	NULL
strongly	NULL
with	NULL
fusion	NULL
proteins	NULL
10	NULL
to	NULL
12	NULL
(	NULL
for	NULL
an	NULL
example	NULL
,	NULL
see	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

These	NULL
data	NULL
localize	NULL
a	NULL
major	NULL
antigenic	NULL
region	NULL
in	NULL
the	NULL
carboxy-terminal	NULL
half	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
between	NULL
amino	NULL
acids	NULL
89	NULL
and	NULL
102	NULL
.	NULL

None	NULL
of	NULL
10	NULL
sera	NULL
without	NULL
serological	NULL
HBV	NULL
markers	NULL
was	NULL
positive	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
this	NULL
demonstrates	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
immunoblot	NULL
assays	NULL
.	NULL

Only	NULL
21	NULL
of	NULL
the	NULL
50	NULL
anti-HBx	NULL
antibody-positive	NULL
sera	NULL
reacted	NULL
with	NULL
amino-terminal	NULL
sequences	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
(	NULL
for	NULL
representative	NULL
examples	NULL
see	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
E	NULL
,	NULL
and	NULL
F	NULL
)	NULL
.	NULL

Fusion	NULL
protein	NULL
2	NULL
carrying	NULL
the	NULL
first	NULL
12	NULL
amino	NULL
acids	NULL
of	NULL
HBx	NULL
did	NULL
not	NULL
react	NULL
with	NULL
any	NULL
of	NULL
the	NULL
sera	NULL
tested	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
the	NULL
possible	NULL
absence	NULL
of	NULL
antigenicity	NULL
at	NULL
the	NULL
amino-terminal	NULL
end	NULL
and	NULL
indicate	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
antigenic	NULL
region	NULL
with	NULL
lower	NULL
immunogenicity	NULL
located	NULL
downstream	NULL
therefrom	NULL
.	NULL

None	NULL
of	NULL
the	NULL
sera	NULL
reacted	NULL
with	NULL
fusion	NULL
protein	NULL
5	NULL
covering	NULL
HBx	NULL
amino	NULL
acids	NULL
10	NULL
to	NULL
32	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
reactivity	NULL
is	NULL
probably	NULL
not	NULL
due	NULL
to	NULL
the	NULL
low	NULL
amount	NULL
of	NULL
fusion	NULL
protein	NULL
expressed	NULL
,	NULL
because	NULL
a	NULL
monoclonal	NULL
antibody	NULL
to	NULL
HBx	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
to	NULL
MS2	NULL
protein	NULL
immunostained	NULL
the	NULL
fusion	NULL
protein	NULL
very	NULL
efficiently	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
amino-terminal	NULL
sequences	NULL
1	NULL
to	NULL
32	NULL
are	NULL
apparently	NULL
not	NULL
antigenic	NULL
in	NULL
this	NULL
assay	NULL
.	NULL

A	NULL
similar	NULL
observation	NULL
has	NULL
been	NULL
made	NULL
with	NULL
carboxy-ter-	NULL
minal	NULL
HBx	NULL
sequences	NULL
.	NULL

By	NULL
immunoblotting	NULL
,	NULL
only	NULL
2	NULL
of	NULL
the	NULL
52	NULL
human	NULL
sera	NULL
tested	NULL
reacted	NULL
strongly	NULL
with	NULL
fusion	NULL
proteins	NULL
16	NULL
and	NULL
17	NULL
covering	NULL
HBx	NULL
amino	NULL
acids	NULL
139	NULL
to	NULL
154	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
(	NULL
one	NULL
example	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3F	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
low	NULL
antigenicity	NULL
for	NULL
carboxy-terminal	NULL
HBx	NULL
sequences	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
immunoblot	NULL
analysis	NULL
indicated	NULL
one	NULL
immunodominant	NULL
antigenic	NULL
region	NULL
between	NULL
amino	NULL
acids	NULL
89	NULL
and	NULL
102	NULL
,	NULL
and	NULL
less	NULL
high	NULL
,	NULL
infrequent	NULL
antigenicity	NULL
of	NULL
amino-	NULL
and	NULL
carboxy-terminal	NULL
regions	NULL
on	NULL
the	NULL
HBx	NULL
protein	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
HBx	NULL
epitopes	NULL
by	NULL
ELISAs	NULL
with	NULL
synthetic	NULL
peptides	NULL
.	NULL

To	NULL
precisely	NULL
map	NULL
the	NULL
epitopes	NULL
and	NULL
to	NULL
search	NULL
for	NULL
other	NULL
epitopes	NULL
which	NULL
may	NULL
not	NULL
be	NULL
detectable	NULL
by	NULL
immunoblotting	NULL
,	NULL
15	NULL
chemically	NULL
synthesized	NULL
,	NULL
partially	NULL
overlapping	NULL
peptides	NULL
spanning	NULL
the	NULL
whole	NULL
HBx	NULL
protein	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
were	NULL
used	NULL
as	NULL
substrates	NULL
in	NULL
ELISAs	NULL
.	NULL

Anti-HBx-positive	NULL
sera	NULL
from	NULL
four	NULL
different	NULL
groups	NULL
of	NULL
patients	NULL
were	NULL
investigated	NULL
as	NULL
fol-lows	NULL
:	NULL
HBV	NULL
-infected	NULL
patients	NULL
with	NULL
acute	NULL
or	NULL
chronic	NULL
hepatitis	NULL
,	NULL
asymptomatic	NULL
chronic	NULL
HBV	NULL
carriers	NULL
,	NULL
and	NULL
chronic	NULL
carriers	NULL
who	NULL
had	NULL
developed	NULL
HCC	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Sera	NULL
were	NULL
considered	NULL
reactive	NULL
with	NULL
an	NULL
HBx	NULL
peptide	NULL
when	NULL
the	NULL
absorbance	NULL
values	NULL
in	NULL
an	NULL
ELISA	NULL
were	NULL
greater	NULL
than	NULL
3	NULL
standard	NULL
deviations	NULL
above	NULL
the	NULL
mean	NULL
obtained	NULL
with	NULL
11	NULL
serum	NULL
samples	NULL
of	NULL
patients	NULL
without	NULL
any	NULL
HBV	NULL
markers	NULL
.	NULL

Sera	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
and	NULL
HCC	NULL
frequently	NULL
reacted	NULL
with	NULL
peptides	NULL
1	NULL
and	NULL
15	NULL
,	NULL
representing	NULL
the	NULL
amino-	NULL
and	NULL
carboxy-terminal	NULL
ends	NULL
of	NULL
HBx	NULL
.	NULL

Frequent	NULL
reaction	NULL
was	NULL
also	NULL
observed	NULL
with	NULL
peptide	NULL
3	NULL
,	NULL
whose	NULL
sequence	NULL
is	NULL
almost	NULL
completely	NULL
embedded	NULL
(	NULL
except	NULL
for	NULL
three	NULL
amino	NULL
acids	NULL
)	NULL
in	NULL
HBx	NULL
sequences	NULL
of	NULL
fusion	NULL
protein	NULL
5	NULL
(	NULL
which	NULL
was	NULL
always	NULL
negative	NULL
by	NULL
immunoblotting	NULL
)	NULL
,	NULL
and	NULL
with	NULL
peptides	NULL
6	NULL
,	NULL
12	NULL
,	NULL
and	NULL
13	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
by	NULL
immunoblotting	NULL
,	NULL
this	NULL
indicates	NULL
the	NULL
frequent	NULL
occurrence	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
human	NULL
sera	NULL
2806	NULL
STEMLER	NULL
ET	NULL
AL	NULL
.	NULL

MAARLCCQLD	NULL
PARDVLCLRP	NULL
VGAESCGRPF	NULL
SGSLGTLSSP	NULL
SPSAVPTDHG	NULL
AHLSLRGLPV	NULL
CAFSSAGPCA	NULL
LRFTSARRME	NULL
TTVNAHQILP	NULL
KVLHKRTLGL	NULL
SAMSTTDLEA	NULL
YFKDCLFKOW	NULL
EELGEEIRLK	NULL
VFVLGGCRHK	NULL
LVCAPAPCNF	NULL
FTSA	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
and	NULL
location	NULL
of	NULL
the	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
(	NULL
dotted	NULL
bars	NULL
)	NULL
used	NULL
for	NULL
ELISAs	NULL
and	NULL
in	NULL
competition	NULL
experiments	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

which	NULL
bind	NULL
to	NULL
several	NULL
independent	NULL
epitopes	NULL
located	NULL
close	NULL
to	NULL
or	NULL
directly	NULL
at	NULL
amino-	NULL
and	NULL
carboxy-terminal	NULL
ends	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
.	NULL

Except	NULL
for	NULL
five	NULL
sera	NULL
,	NULL
all	NULL
anti-HBx	NULL
antibody-positive	NULL
sera	NULL
reacted	NULL
very	NULL
strongly	NULL
with	NULL
at	NULL
least	NULL
one	NULL
of	NULL
the	NULL
three	NULL
peptides	NULL
9	NULL
to	NULL
11	NULL
,	NULL
and	NULL
this	NULL
reaction	NULL
was	NULL
usually	NULL
stronger	NULL
than	NULL
with	NULL
any	NULL
other	NULL
peptide	NULL
,	NULL
as	NULL
reflected	NULL
by	NULL
the	NULL
high	NULL
absorbance	NULL
values	NULL
.	NULL

These	NULL
data	NULL
localize	NULL
an	NULL
immunodominant	NULL
antigenic	NULL
region	NULL
with	NULL
several	NULL
epitopes	NULL
between	NULL
amino	NULL
acids	NULL
85	NULL
and	NULL
110	NULL
which	NULL
frequently	NULL
elicit	NULL
high	NULL
titers	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
.	NULL

Infre-quently	NULL
,	NULL
anti-HBx	NULL
antibodies	NULL
bound	NULL
to	NULL
peptides	NULL
2	NULL
,	NULL
4	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
14	NULL
,	NULL
and	NULL
not	NULL
a	NULL
single	NULL
serum	NULL
reacted	NULL
with	NULL
peptide	NULL
7	NULL
,	NULL
suggesting	NULL
the	NULL
existence	NULL
of	NULL
small	NULL
HBx	NULL
regions	NULL
with	NULL
little	NULL
or	NULL
no	NULL
immunogenicity	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
anti-HBx	NULL
antibody	NULL
titers	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
various	NULL
HBx	NULL
peptide	NULL
ELISAs	NULL
were	NULL
usually	NULL
lower	NULL
in	NULL
patients	NULL
with	NULL
acute	NULL
infection	NULL
and	NULL
in	NULL
asymptomatic	NULL
carriers	NULL
than	NULL
in	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
and	NULL
HCC	NULL
.	NULL

Competition	NULL
assay	NULL
with	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
most	NULL
antigenic	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
carry	NULL
a	NULL
single	NULL
common	NULL
or	NULL
two	NULL
nonoverlapping	NULL
epitopes	NULL
and	NULL
whether	NULL
immunoblotting	NULL
and	NULL
HBx	NULL
peptide	NULL
ELISAs	NULL
detected	NULL
the	NULL
same	NULL
TABLE	NULL
1	NULL
.	NULL

ELISA	NULL
with	NULL
HBx	NULL
peptides	NULL
and	NULL
anti-HBx-positive	NULL
human	NULL
sera	NULL
``	NULL
a	NULL
Sera	NULL
were	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
hepatitis	NULL
(	NULL
AH	NULL
)	NULL
,	NULL
asymptomatic	NULL
chronic	NULL
HBV	NULL
carriers	NULL
(	NULL
ASH	NULL
)	NULL
,	NULL
and	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
(	NULL
CH	NULL
)	NULL
and	NULL
hepatocellular	NULL
carcinoma	NULL
(	NULL
HCC	NULL
)	NULL
.	NULL

P	NULL
,	NULL
Peptide	NULL
.	NULL

w	NULL
,	NULL
Serum	NULL
which	NULL
reacted	NULL
with	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
and	NULL
which	NULL
was	NULL
used	NULL
in	NULL
the	NULL
experiment	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
A	NULL
.	NULL

ine	NULL
gon	NULL
got	NULL
dirt	NULL
(	NULL
Bh	NULL
mome	NULL
mre	NULL
tand	NULL
oon	NULL
toe	NULL
gong	NULL
@	NULL
*	NULL
-s	NULL
-	NULL
-	NULL
law	NULL
”	NULL
r	NULL
?	NULL

<	NULL
e	NULL
I	NULL
P	NULL
B.	NULL
Cine	NULL
Qing	NULL
a-	NULL
Que	NULL
:	NULL
6-2	NULL
o-	NULL
»	NULL
cure	NULL
gong	NULL
ues	NULL
fug	NULL
c	NULL
44	NULL
tg	NULL
o	NULL
+	NULL
anni	NULL
#	NULL
«	NULL
ase	NULL
wh	NULL
and	NULL
#	NULL
guage	NULL
:	NULL
@	NULL
<	NULL
r	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Identification	NULL
of	NULL
HBx	NULL
epitopes	NULL
by	NULL
immunoblot	NULL
analysis	NULL
by	NULL
using	NULL
sera	NULL
preincubated	NULL
with	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
.	NULL

Immunoblot	NULL
with	NULL
recombinant	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
and	NULL
serum	NULL
of	NULL
a	NULL
chronic	NULL
HBV	NULL
carrier	NULL
(	NULL
HBsAg*	NULL
HBeAg*	NULL
DNA	NULL
*	NULL
)	NULL
not	NULL
preincubated	NULL
with	NULL
peptides	NULL
(	NULL
A	NULL
)	NULL
;	NULL
same	NULL
serum	NULL
preincubated	NULL
with	NULL
HBx	NULL
peptides	NULL
9	NULL
(	NULL
B	NULL
)	NULL
or	NULL
10	NULL
(	NULL
C	NULL
)	NULL
;	NULL
same	NULL
serum	NULL
with	NULL
a	NULL
mixture	NULL
of	NULL
HBx	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
(	NULL
D	NULL
)	NULL
.	NULL

The	NULL
reactivity	NULL
pattern	NULL
of	NULL
this	NULL
serum	NULL
in	NULL
the	NULL
HBx	NULL
peptide	NULL
ELISA	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
by	NULL
a	NULL
star	NULL
.	NULL

Lanes	NULL
are	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3.	NULL
epitopes	NULL
,	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
were	NULL
used	NULL
as	NULL
competitors	NULL
in	NULL
immunoblots	NULL
with	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
a	NULL
serum	NULL
was	NULL
used	NULL
which	NULL
strongly	NULL
reacted	NULL
in	NULL
immunoblotting	NULL
with	NULL
fusion	NULL
proteins	NULL
10	NULL
to	NULL
12	NULL
and	NULL
weakly	NULL
reacted	NULL
with	NULL
fusion	NULL
protein	NULL
15	NULL
(	NULL
Fig	NULL
.	NULL

SA	NULL
)	NULL
and	NULL
in	NULL
ELISA	NULL
with	NULL
the	NULL
corresponding	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
(	NULL
Table	NULL
1	NULL
,	NULL
star	NULL
)	NULL
.	NULL

The	NULL
reaction	NULL
with	NULL
fusion	NULL
protein	NULL
15	NULL
but	NULL
not	NULL
with	NULL
peptides	NULL
13	NULL
to	NULL
15	NULL
already	NULL
indicates	NULL
that	NULL
some	NULL
epitopes	NULL
are	NULL
detected	NULL
by	NULL
immunoblotting	NULL
but	NULL
not	NULL
by	NULL
our	NULL
peptide	NULL
ELISAs	NULL
.	NULL

Preincubation	NULL
of	NULL
this	NULL
serum	NULL
with	NULL
peptide	NULL
9	NULL
strongly	NULL
reduced	NULL
the	NULL
immunoreaction	NULL
with	NULL
fusion	NULL
proteins	NULL
10	NULL
and	NULL
11	NULL
but	NULL
left	NULL
virtually	NULL
unchanged	NULL
that	NULL
with	NULL
fusion	NULL
protein	NULL
12	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
the	NULL
presence	NULL
of	NULL
at	NULL
least	NULL
two	NULL
nonoverlapping	NULL
epitopes	NULL
in	NULL
the	NULL
immunodominant	NULL
region	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
reaction	NULL
of	NULL
the	NULL
same	NULL
serum	NULL
after	NULL
preincubation	NULL
with	NULL
peptide	NULL
10	NULL
,	NULL
which	NULL
reduced	NULL
strongly	NULL
the	NULL
signals	NULL
with	NULL
fusion	NULL
protein	NULL
12	NULL
and	NULL
also	NULL
(	NULL
but	NULL
less	NULL
strongly	NULL
)	NULL
fusion	NULL
proteins	NULL
10	NULL
and	NULL
11	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Preincubation	NULL
of	NULL
the	NULL
serum	NULL
with	NULL
both	NULL
peptides	NULL
completely	NULL
abolished	NULL
reactivity	NULL
with	NULL
fusion	NULL
protein	NULL
11	NULL
and	NULL
strongly	NULL
reduced	NULL
the	NULL
immune	NULL
reaction	NULL
with	NULL
fusion	NULL
proteins	NULL
10	NULL
and	NULL
12	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

These	NULL
changes	NULL
in	NULL
immunoreactivity	NULL
after	NULL
preincubation	NULL
with	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
are	NULL
specific	NULL
,	NULL
because	NULL
the	NULL
reaction	NULL
with	NULL
fusion	NULL
protein	NULL
15	NULL
remained	NULL
unchanged	NULL
and	NULL
preincubation	NULL
with	NULL
HBx	NULL
peptides	NULL
5	NULL
and	NULL
11	NULL
did	NULL
not	NULL
reduce	NULL
the	NULL
reactivity	NULL
with	NULL
any	NULL
of	NULL
the	NULL
fusion	NULL
ANTIGENICITY	NULL
OF	NULL
HEPATITIS	NULL
B	NULL
VIRUS	NULL
X	NULL
PROTEIN	NULL
2807	NULL
proteins	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
the	NULL
existence	NULL
of	NULL
at	NULL
least	NULL
two	NULL
major	NULL
nonoverlapping	NULL
epitopes	NULL
in	NULL
the	NULL
major	NULL
antigenic	NULL
region	NULL
which	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
peptides	NULL
9	NULL
and	NULL
10	NULL
and	NULL
show	NULL
that	NULL
there	NULL
are	NULL
additional	NULL
minor	NULL
epitopes	NULL
in	NULL
this	NULL
region	NULL
which	NULL
are	NULL
not	NULL
exhibited	NULL
or	NULL
carried	NULL
by	NULL
either	NULL
of	NULL
these	NULL
peptides	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
by	NULL
epitope	NULL
mapping	NULL
the	NULL
specificity	NULL
of	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
and	NULL
chronic	NULL
HBV	NULL
infection	NULL
with	NULL
and	NULL
without	NULL
HCC	NULL
.	NULL

Almost	NULL
all	NULL
sera	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
antibodies	NULL
to	NULL
more	NULL
than	NULL
one	NULL
epitope	NULL
.	NULL

The	NULL
carboxy-terminal	NULL
half	NULL
of	NULL
the	NULL
HBx	NULL
antigen	NULL
was	NULL
the	NULL
most	NULL
frequent	NULL
target	NULL
for	NULL
anti-HBx	NULL
antibodies	NULL
in	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
viral	NULL
hepatitis	NULL
and	NULL
contained	NULL
an	NULL
immunodominant	NULL
antigenic	NULL
region	NULL
approximately	NULL
25	NULL
amino	NULL
acids	NULL
long	NULL
in	NULL
which	NULL
two	NULL
major	NULL
epitopes	NULL
were	NULL
identified	NULL
.	NULL

The	NULL
highest	NULL
titers	NULL
and	NULL
more	NULL
heterogeneous	NULL
anti-HBx	NULL
antibody	NULL
specificities	NULL
tended	NULL
to	NULL
occur	NULL
in	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
hepatitis	NULL
,	NULL
whereas	NULL
low	NULL
titers	NULL
and	NULL
fewer	NULL
epitopes	NULL
were	NULL
characteristic	NULL
for	NULL
sera	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
hepatitis	NULL
and	NULL
for	NULL
asymptomatic	NULL
chronic	NULL
carriers	NULL
.	NULL

The	NULL
immunodominant	NULL
antigenic	NULL
domain	NULL
is	NULL
located	NULL
between	NULL
amino	NULL
acid	NULL
positions	NULL
85	NULL
and	NULL
110	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
based	NULL
on	NULL
two	NULL
findings	NULL
.	NULL

First	NULL
,	NULL
most	NULL
of	NULL
the	NULL
anti-HBx-positive	NULL
sera	NULL
tested	NULL
reacted	NULL
with	NULL
this	NULL
domain	NULL
by	NULL
immunoblotting	NULL
with	NULL
MS2-HBx	NULL
fusion	NULL
protein	NULL
and	NULL
in	NULL
ELISAs	NULL
with	NULL
synthetic	NULL
HBx	NULL
peptides	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
anti-HBx	NULL
antibodies	NULL
with	NULL
the	NULL
highest	NULL
titers	NULL
(	NULL
as	NULL
estimated	NULL
from	NULL
HBx	NULL
peptide	NULL
ELISA	NULL
data	NULL
)	NULL
were	NULL
directed	NULL
to	NULL
two	NULL
epitopes	NULL
of	NULL
this	NULL
region	NULL
.	NULL

The	NULL
antigenicity	NULL
of	NULL
this	NULL
region	NULL
is	NULL
consistent	NULL
with	NULL
computer	NULL
algorithms	NULL
which	NULL
predict	NULL
a	NULL
relatively	NULL
high	NULL
antigenic	NULL
index	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
its	NULL
rather	NULL
high	NULL
hydrophilicity	NULL
,	NULL
flexibility	NULL
,	NULL
and	NULL
probability	NULL
of	NULL
surface	NULL
location	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Antibodies	NULL
reacting	NULL
with	NULL
the	NULL
amino-	NULL
and	NULL
carboxy-terminal	NULL
ends	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
were	NULL
not	NULL
found	NULL
by	NULL
immunoblotting	NULL
with	NULL
the	NULL
corresponding	NULL
MS2-HBx	NULL
fusion	NULL
proteins	NULL
but	NULL
were	NULL
strongly	NULL
reactive	NULL
in	NULL
ELISAs	NULL
with	NULL
peptides	NULL
.	NULL

The	NULL
nonreactive	NULL
fusion	NULL
protein	NULL
2	NULL
contained	NULL
only	NULL
12	NULL
X	NULL
protein-specific	NULL
amino-terminal	NULL
amino	NULL
acids	NULL
,	NULL
suggesting	NULL
nonantigenicity	NULL
of	NULL
the	NULL
amino-terminal	NULL
HBx	NULL
sequences	NULL
.	NULL

The	NULL
15-amino-acid	NULL
amino-terminal	NULL
HBx	NULL
peptide	NULL
,	NULL
however	NULL
,	NULL
reacted	NULL
strongly	NULL
and	NULL
thus	NULL
contains	NULL
at	NULL
least	NULL
one	NULL
epitope	NULL
.	NULL

Taking	NULL
into	NULL
account	NULL
the	NULL
negative	NULL
reaction	NULL
with	NULL
fusion	NULL
protein	NULL
2	NULL
,	NULL
this	NULL
epitope	NULL
could	NULL
be	NULL
located	NULL
at	NULL
the	NULL
carboxy-terminal	NULL
end	NULL
of	NULL
peptide	NULL
1	NULL
.	NULL

Alterna-tively	NULL
,	NULL
it	NULL
may	NULL
be	NULL
located	NULL
at	NULL
the	NULL
amino-terminal	NULL
end	NULL
and	NULL
is	NULL
not	NULL
recognized	NULL
when	NULL
fused	NULL
to	NULL
other	NULL
sequences	NULL
such	NULL
as	NULL
MS2	NULL
.	NULL

A	NULL
similar	NULL
reasoning	NULL
can	NULL
be	NULL
applied	NULL
to	NULL
the	NULL
carboxy	NULL
terminus	NULL
of	NULL
the	NULL
HBx	NULL
protein	NULL
.	NULL

Fusion	NULL
protein	NULL
16	NULL
reacted	NULL
only	NULL
rarely	NULL
in	NULL
immunoblotting	NULL
(	NULL
although	NULL
it	NULL
contains	NULL
16	NULL
carboxy-terminal	NULL
HBx-specific	NULL
amino	NULL
acids	NULL
)	NULL
,	NULL
whereas	NULL
peptide	NULL
15	NULL
containing	NULL
the	NULL
same	NULL
HBx	NULL
sequence	NULL
minus	NULL
two	NULL
amino	NULL
acids	NULL
reacted	NULL
frequently	NULL
with	NULL
anti-HBx	NULL
antibody-positive	NULL
sera	NULL
.	NULL

A	NULL
simple	NULL
explanation	NULL
for	NULL
this	NULL
observation	NULL
is	NULL
to	NULL
assume	NULL
the	NULL
existence	NULL
of	NULL
strongly	NULL
conformation-dependent	NULL
epitopes	NULL
which	NULL
can	NULL
not	NULL
be	NULL
built	NULL
up	NULL
in	NULL
fusion	NULL
proteins	NULL
fixed	NULL
to	NULL
nitrocellulose	NULL
,	NULL
whereas	NULL
these	NULL
epitopes	NULL
are	NULL
well	NULL
represented	NULL
in	NULL
peptide	NULL
15	NULL
in	NULL
microdilution	NULL
plate	NULL
fixed	NULL
form	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
conformation	NULL
in	NULL
epitope	NULL
recognition	NULL
is	NULL
amply	NULL
documented	NULL
for	NULL
other	NULL
proteins	NULL
and	NULL
peptides	NULL
(	NULL
49	NULL
)	NULL
.	NULL

The	NULL
immunodominant	NULL
region	NULL
is	NULL
highly	NULL
conserved	NULL
in	NULL
all	NULL
HBV	NULL
isolate	NULL
sequences	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Anti-HBx	NULL
antibody-positive	NULL
sera	NULL
reacting	NULL
with	NULL
the	NULL
HBx	NULL
protein	NULL
of	NULL
a	NULL
specific	NULL
subtype	NULL
only	NULL
should	NULL
therefore	NULL
be	NULL
rare	NULL
or	NULL
not	NULL
exist	NULL
at	NULL
all	NULL
.	NULL

2808	NULL
STEMLER	NULL
ET	NULL
AL	NULL
.	NULL

Because	NULL
of	NULL
similar	NULL
codon	NULL
usage	NULL
of	NULL
the	NULL
X	NULL
gene	NULL
and	NULL
genes	NULL
of	NULL
eucaryotic	NULL
cells	NULL
,	NULL
the	NULL
X	NULL
gene	NULL
was	NULL
speculated	NULL
to	NULL
be	NULL
of	NULL
cellular	NULL
origin	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
show	NULL
that	NULL
most	NULL
of	NULL
the	NULL
HBx	NULL
sequences	NULL
can	NULL
be	NULL
immunogenic	NULL
in	NULL
humans	NULL
.	NULL

Thus	NULL
,	NULL
if	NULL
HBx	NULL
is	NULL
of	NULL
cellular	NULL
origin	NULL
and	NULL
if	NULL
some	NULL
sequence	NULL
similarity	NULL
with	NULL
the	NULL
cellular	NULL
ancestor	NULL
protein	NULL
still	NULL
exists	NULL
,	NULL
some	NULL
of	NULL
the	NULL
HBx	NULL
antibodies	NULL
may	NULL
,	NULL
by	NULL
cross-reaction	NULL
,	NULL
induce	NULL
an	NULL
autoimmune	NULL
response	NULL
to	NULL
the	NULL
cellular	NULL
homolog	NULL
.	NULL

This	NULL
would	NULL
represent	NULL
a	NULL
special	NULL
case	NULL
of	NULL
molecular	NULL
mimicry	NULL
which	NULL
is	NULL
known	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
induction	NULL
of	NULL
some	NULL
autoimmune	NULL
diseases	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Whether	NULL
the	NULL
anti-HBx	NULL
antibodies	NULL
cross-react	NULL
with	NULL
a	NULL
related	NULL
cellular	NULL
protein	NULL
can	NULL
be	NULL
experimentally	NULL
tested	NULL
by	NULL
using	NULL
highly	NULL
polyspecific	NULL
anti-HBx	NULL
antisera	NULL
as	NULL
identified	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Such	NULL
investigations	NULL
may	NULL
also	NULL
provide	NULL
clues	NULL
to	NULL
our	NULL
understanding	NULL
of	NULL
autoimmune	NULL
phenomena	NULL
which	NULL
are	NULL
occasionally	NULL
associated	NULL
with	NULL
HBV	NULL
infection	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
HBx	NULL
protein	NULL
is	NULL
a	NULL
transactivator	NULL
of	NULL
transcription	NULL
in	NULL
the	NULL
cytoplasm	NULL
and	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
4	NULL
,	NULL
19	NULL
,	NULL
20	NULL
,	NULL
21a	NULL
,	NULL
37	NULL
,	NULL
43	NULL
)	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
how	NULL
HBx	NULL
is	NULL
presented	NULL
to	NULL
the	NULL
immune	NULL
system	NULL
of	NULL
the	NULL
host	NULL
.	NULL

It	NULL
may	NULL
be	NULL
released	NULL
from	NULL
necrotic	NULL
hepatocytes	NULL
as	NULL
a	NULL
mono-	NULL
or	NULL
polymeric	NULL
protein	NULL
with	NULL
or	NULL
without	NULL
associated	NULL
cellular	NULL
proteins	NULL
,	NULL
it	NULL
may	NULL
be	NULL
secreted	NULL
,	NULL
or	NULL
it	NULL
may	NULL
be	NULL
processed	NULL
and	NULL
presented	NULL
as	NULL
peptides	NULL
in	NULL
free	NULL
form	NULL
or	NULL
associated	NULL
with	NULL
cell	NULL
membranes	NULL
.	NULL

The	NULL
many	NULL
epitopes	NULL
scattered	NULL
almost	NULL
all	NULL
over	NULL
the	NULL
HBx	NULL
protein	NULL
sequence	NULL
as	NULL
identified	NULL
here	NULL
suggest	NULL
the	NULL
involvement	NULL
of	NULL
processing	NULL
of	NULL
HBx	NULL
as	NULL
one	NULL
driving	NULL
force	NULL
of	NULL
the	NULL
multispecific	NULL
immune	NULL
response	NULL
.	NULL

Hybrid	NULL
HBx-cell	NULL
fusion	NULL
proteins	NULL
were	NULL
speculated	NULL
to	NULL
be	NULL
expressed	NULL
from	NULL
integrated	NULL
HBV	NULL
DNA	NULL
,	NULL
which	NULL
is	NULL
often	NULL
found	NULL
in	NULL
liver	NULL
tissue	NULL
of	NULL
chronic	NULL
carriers	NULL
and	NULL
of	NULL
patients	NULL
with	NULL
hepatocellular	NULL
carcinomas	NULL
,	NULL
and	NULL
from	NULL
flanking	NULL
cellular	NULL
sequences	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
30	NULL
,	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Such	NULL
proteins	NULL
could	NULL
assume	NULL
a	NULL
different	NULL
conformation	NULL
and	NULL
therefore	NULL
exhibit	NULL
different	NULL
epitopes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
because	NULL
of	NULL
the	NULL
frequent	NULL
loss	NULL
of	NULL
carboxy-terminal	NULL
HBx	NULL
sequences	NULL
by	NULL
preferential	NULL
integration	NULL
at	NULL
the	NULL
cohesive	NULL
end	NULL
region	NULL
of	NULL
the	NULL
HBV	NULL
genome	NULL
(	NULL
32	NULL
)	NULL
,	NULL
antibodies	NULL
to	NULL
carboxy-terminal	NULL
HBx	NULL
sequences	NULL
might	NULL
be	NULL
underrepre-sented	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
these	NULL
patients	NULL
.	NULL

We	NULL
have	NULL
addressed	NULL
these	NULL
questions	NULL
by	NULL
determining	NULL
the	NULL
anti-HBx	NULL
antibody	NULL
specificities	NULL
in	NULL
the	NULL
few	NULL
anti-HBx	NULL
antibody-positive	NULL
sera	NULL
of	NULL
HCC	NULL
patients	NULL
we	NULL
had	NULL
available	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
do	NULL
not	NULL
indicate	NULL
a	NULL
different	NULL
set	NULL
of	NULL
anti-HBx	NULL
antibody	NULL
specificities	NULL
or	NULL
an	NULL
under-representation	NULL
of	NULL
antibodies	NULL
to	NULL
carboxy-terminal	NULL
sequences	NULL
in	NULL
sera	NULL
of	NULL
HCC	NULL
patients	NULL
.	NULL

Such	NULL
changes	NULL
in	NULL
antibody	NULL
specificities	NULL
may	NULL
,	NULL
however	NULL
,	NULL
only	NULL
become	NULL
apparent	NULL
long	NULL
after	NULL
HBV	NULL
replication	NULL
has	NULL
ceased	NULL
and	NULL
after	NULL
the	NULL
disappearance	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
full-length	NULL
wild-type	NULL
HBx	NULL
protein	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
warranted	NULL
to	NULL
investigate	NULL
this	NULL
in	NULL
more	NULL
detail	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
.	NULL

We	NULL
thank	NULL
H.	NULL
H.	NULL
Guldner	NULL
,	NULL
F.	NULL
Schodel	NULL
,	NULL
and	NULL
G.	NULL
Wildner	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
G.	NULL
Wildner	NULL
for	NULL
providing	NULL
the	NULL
monoclonal	NULL
M52	NULL
antibody	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Beasley	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
L.-Y	NULL
.	NULL

Hwang	NULL
,	NULL
C.-C.	NULL
Lin	NULL
,	NULL
and	NULL
C.	NULL
S.	NULL
Chien	NULL
.	NULL

1981	NULL
.	NULL

Hepatocellular	NULL
carcinoma	NULL
and	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

Lancet	NULL
ii	NULL
:	NULL
1129-1133	NULL
.	NULL

2	NULL
.	NULL

Chang	NULL
,	NULL
C.	NULL
,	NULL
K.-S.	NULL
Jeng	NULL
,	NULL
C.-P.	NULL
Hu	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

Lo	NULL
,	NULL
T.-S.	NULL
Su	NULL
,	NULL
L.-P.	NULL
Ting	NULL
,	NULL
C.-K.	NULL
Chou	NULL
,	NULL
S.-H.	NULL
Han	NULL
,	NULL
E.	NULL
Pfaff	NULL
,	NULL
J.	NULL
Salfeld	NULL
,	NULL
and	NULL
H.	NULL
Schaller	NULL
.	NULL

1987	NULL
.	NULL

Production	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
in	NULL
vitro	NULL
by	NULL
transient	NULL
expression	NULL
of	NULL
cloned	NULL
HBV	NULL
DNA	NULL
in	NULL
a	NULL
hepatoma	NULL
cell	NULL
line	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:675-680	NULL
.	NULL

3	NULL
.	NULL

Chang	NULL
,	NULL
L.-J	NULL
.	NULL

,	NULL
J.	NULL
Dienstag	NULL
,	NULL
D.	NULL
Ganem	NULL
,	NULL
and	NULL
H.	NULL
Varmus	NULL
.	NULL

1989	NULL
.	NULL

Detection	NULL
of	NULL
antibodies	NULL
against	NULL
hepatitis	NULL
B	NULL
virus	NULL
polymerase	NULL
antigen	NULL
in	NULL
hepatitis	NULL
B	NULL
virus	NULL
infected	NULL
patients	NULL
.	NULL

Hepatology	NULL
10	NULL
:	NULL
J.	NULL
ViroL	NULL
.	NULL

332-335	NULL
.	NULL

4	NULL
.	NULL

Chisaka	NULL
,	NULL
O.	NULL
,	NULL
K.	NULL
Araki	NULL
,	NULL
T.	NULL
Ochiya	NULL
,	NULL
T.	NULL
Tsurimoto	NULL
,	NULL
W.	NULL
Hiranyaw-asitte-Attatippaholkun	NULL
,	NULL
N.	NULL
Yanaihara	NULL
,	NULL
and	NULL
K.	NULL
Matsubara	NULL
.	NULL

1987	NULL
.	NULL

Purification	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
gene	NULL
X	NULL
product	NULL
synthesized	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
its	NULL
detection	NULL
in	NULL
human	NULL
hepatoblastoma	NULL
cell	NULL
line	NULL
producing	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

Gene	NULL
60:183-189	NULL
.	NULL

5	NULL
.	NULL

Colgrove	NULL
,	NULL
R.	NULL
,	NULL
G.	NULL
Simon	NULL
,	NULL
and	NULL
D.	NULL
Ganem	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
homologous	NULL
and	NULL
heterologous	NULL
genes	NULL
by	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
gene	NULL
product	NULL
in	NULL
cells	NULL
permissive	NULL
for	NULL
viral	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4019-4026	NULL
.	NULL

6	NULL
.	NULL

Dejean	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Sonigo	NULL
,	NULL
S.	NULL
Wain-Hobson	NULL
,	NULL
and	NULL
P.	NULL
Tiollais	NULL
.	NULL

1984	NULL
.	NULL

Specific	NULL
hepatitis	NULL
B	NULL
virus	NULL
integration	NULL
in	NULL
hepatocellular	NULL
carcinoma	NULL
DNA	NULL
through	NULL
a	NULL
viral	NULL
l1-base-pair	NULL
direct	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:5350-5354	NULL
.	NULL

7	NULL
.	NULL

Desmet	NULL
,	NULL
V.	NULL
J	NULL
.	NULL

1988	NULL
.	NULL

Liver	NULL
lesions	NULL
in	NULL
hepatitis	NULL
B	NULL
viral	NULL
infections	NULL
.	NULL

Yale	NULL
J.	NULL
Biol	NULL
.	NULL

Med	NULL
.	NULL

61:61-83	NULL
.	NULL

8	NULL
.	NULL

Dretzen	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Ballard	NULL
,	NULL
P.	NULL
Sassone-Corsi	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
reliable	NULL
method	NULL
for	NULL
the	NULL
recovery	NULL
of	NULL
DNA	NULL
fragments	NULL
from	NULL
agarose	NULL
and	NULL
acrylamide	NULL
gels	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

112:295-298	NULL
.	NULL

9	NULL
.	NULL

Elfassi	NULL
,	NULL
E.	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Dienstag	NULL
.	NULL

1986	NULL
.	NULL

Detection	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
product	NULL
using	NULL
an	NULL
open	NULL
reading	NULL
frame	NULL
Escherichia	NULL
coli	NULL
expression	NULL
vector	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:2219-2222	NULL
.	NULL

10	NULL
.	NULL

Feitelson	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
L.	NULL
Millman	NULL
,	NULL
G.	NULL
D.	NULL
Duncan	NULL
,	NULL
and	NULL
B.	NULL
S.	NULL
Blumberg	NULL
.	NULL

1988	NULL
.	NULL

Presence	NULL
of	NULL
antibodies	NULL
to	NULL
the	NULL
polymerase	NULL
gene	NULL
product	NULL
(	NULL
s	NULL
)	NULL
of	NULL
hepatitis	NULL
B	NULL
and	NULL
woodchuck	NULL
hepatitis	NULL
virus	NULL
in	NULL
natural	NULL
and	NULL
experimental	NULL
infections	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

24:121-136	NULL
.	NULL

11	NULL
.	NULL

Freytag	NULL
von	NULL
Loringhoven	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Koch	NULL
,	NULL
P.	NULL
H.	NULL
Hofschneider	NULL
,	NULL
and	NULL
R.	NULL
Koshy	NULL
.	NULL

1985	NULL
.	NULL

Co-transcribed	NULL
3	NULL
'	NULL
host	NULL
sequences	NULL
augment	NULL
expression	NULL
of	NULL
integrated	NULL
hepatitis	NULL
virus	NULL
DNA	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

4	NULL
:	NULL
249-255	NULL
.	NULL

12	NULL
.	NULL

Fujinami	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
and	NULL
M.	NULL
B	NULL
.	NULL

A.	NULL
Oldstone	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
mimicry	NULL
as	NULL
a	NULL
mechanism	NULL
for	NULL
virus-induced	NULL
autoimmunity	NULL
.	NULL

Immunol	NULL
.	NULL

Res	NULL
.	NULL

8:3-15	NULL
.	NULL

13	NULL
.	NULL

Galibert	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
Mandart	NULL
,	NULL
E.	NULL
Fitoussi	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
and	NULL
P.	NULL
Char-nay	NULL
.	NULL

1979	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
genome	NULL
(	NULL
subtype	NULL
ayw	NULL
)	NULL
cloned	NULL
in	NULL
E.	NULL
coli	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
281:646-650	NULL
.	NULL

14	NULL
.	NULL

Ganem	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Varmus	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
molecular	NULL
biology	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

56:651-693	NULL
.	NULL

15	NULL
.	NULL

Guldner	NULL
,	NULL
H.	NULL
H.	NULL
,	NULL
H.	NULL
J.	NULL
Netter	NULL
,	NULL
C.	NULL
Szostecki	NULL
,	NULL
H.	NULL
J.	NULL
Lakomek	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1988	NULL
.	NULL

Epitope	NULL
mapping	NULL
with	NULL
a	NULL
recombinant	NULL
human	NULL
p68-kDa	NULL
(	NULL
U1	NULL
)	NULL
ribonucleoprotein	NULL
antigen	NULL
reveals	NULL
heterogeneous	NULL
autoantibody	NULL
profiles	NULL
in	NULL
human	NULL
autoimmune	NULL
sera	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

141:469-475	NULL
.	NULL

16	NULL
.	NULL

Hess	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Stemler	NULL
,	NULL
H.	NULL
Will	NULL
,	NULL
C.	NULL
H.	NULL
Schroder	NULL
,	NULL
J.	NULL
Kithn	NULL
,	NULL
and	NULL
R.	NULL
Braun	NULL
.	NULL

1988	NULL
.	NULL

Frequent	NULL
detection	NULL
of	NULL
antibodies	NULL
to	NULL
hepatitis	NULL
B	NULL
virus	NULL
X-protein	NULL
in	NULL
acute	NULL
,	NULL
chronic	NULL
and	NULL
resolved	NULL
infections	NULL
.	NULL

Med	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

177:195-205	NULL
.	NULL

17	NULL
.	NULL

Jean-Jean	NULL
,	NULL
O.	NULL
,	NULL
M.	NULL
Levrero	NULL
,	NULL
H.	NULL
Will	NULL
,	NULL
M.	NULL
Perricaudet	NULL
,	NULL
and	NULL
J.-M.	NULL
Rossignol	NULL
.	NULL

1989	NULL
.	NULL

Expression	NULL
mechanism	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
(	NULL
HBV	NULL
)	NULL
C	NULL
gene	NULL
and	NULL
biosynthesis	NULL
of	NULL
HBe	NULL
antigen	NULL
.	NULL

Virology	NULL
170:99-106	NULL
.	NULL

18	NULL
.	NULL

Kay	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Mandart	NULL
,	NULL
C.	NULL
Trepo	NULL
,	NULL
and	NULL
F.	NULL
Galibert	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
HBV	NULL
HBx	NULL
gene	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
is	NULL
recognised	NULL
by	NULL
sera	NULL
from	NULL
hepatitis	NULL
patients	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

4:1287-1292	NULL
.	NULL

19	NULL
.	NULL

Ke-Qin	NULL
,	NULL
H.	NULL
,	NULL
H.	NULL
Lian-Jie	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
preliminary	NULL
study	NULL
on	NULL
localization	NULL
of	NULL
HBxAg	NULL
in	NULL
liver	NULL
tissue	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
liver	NULL
disease	NULL
and	NULL
its	NULL
significance	NULL
.	NULL

Chin	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

101:671-674	NULL
.	NULL

20	NULL
.	NULL

Koike	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Akatsuka	NULL
,	NULL
and	NULL
T.	NULL
Miyamura	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
gene	NULL
:	NULL
in	NULL
vitro	NULL
translation	NULL
of	NULL
mRNA	NULL
from	NULL
COS-1	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
X	NULL
gene	NULL
.	NULL

Virology	NULL
163	NULL
:	NULL
233-235	NULL
.	NULL

21	NULL
.	NULL

Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
1970	NULL
.	NULL

Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T4	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
227:680-685	NULL
.	NULL

21a.Levrero	NULL
,	NULL
M.	NULL
,	NULL
O.	NULL
Jean-Jean	NULL
,	NULL
C.	NULL
Balsano	NULL
,	NULL
H.	NULL
Will	NULL
,	NULL
and	NULL
M.	NULL
Perri-caudet	NULL
.	NULL

1990	NULL
.	NULL

Hepatitis	NULL
B	NULL
virus	NULL
(	NULL
HBV	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
cells	NULL
and	NULL
anti-HBx	NULL
antibody	NULL
detection	NULL
in	NULL
chronic	NULL
HBV	NULL
infec-tion	NULL
.	NULL

Virology	NULL
174:299-304	NULL
.	NULL

22	NULL
.	NULL

Liang	NULL
,	NULL
X.-H.	NULL
,	NULL
M.	NULL
Stemler	NULL
,	NULL
H.	NULL
Will	NULL
,	NULL
R.	NULL
Braun	NULL
,	NULL
Z.-Y	NULL
.	NULL

Tang	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
Schroder	NULL
.	NULL

1988	NULL
.	NULL

Low	NULL
incidence	NULL
and	NULL
high	NULL
titers	NULL
of	NULL
antibodies	NULL
to	NULL
hepatitis	NULL
B	NULL
virus	NULL
X-protein	NULL
in	NULL
sera	NULL
of	NULL
Chinese	NULL
patients	NULL
with	NULL
hepatocellular	NULL
carcinoma	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

25:329-337	NULL
.	NULL

Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

Lo	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
M.-L.	NULL
Chien	NULL
,	NULL
and	NULL
Y.-H.	NULL
W.	NULL
Lee	NULL
.	NULL

1988	NULL
.	NULL

Characteristics	NULL
of	NULL
the	NULL
X	NULL
gene	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

Virology	NULL
167:289-292	NULL
.	NULL

Maniatis	NULL
,	NULL
T.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
J.	NULL
Sambrook	NULL
.	NULL

1982	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Manns	NULL
,	NULL
M.	NULL
1989	NULL
.	NULL

Autoantibodies	NULL
and	NULL
antigens	NULL
in	NULL
liver	NULL
dis-eases-updated	NULL
.	NULL

J.	NULL
Hepatol	NULL
.	NULL

9:272-280	NULL
.	NULL

Meyers	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
L.	NULL
Vitvitski	NULL
Trepo	NULL
,	NULL
N.	NULL
Nath	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Sninsky	NULL
.	NULL

1986	NULL
.	NULL

Hepatitis	NULL
B	NULL
virus	NULL
polypeptide	NULL
X	NULL
:	NULL
expression	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
identification	NULL
of	NULL
specific	NULL
antibodies	NULL
in	NULL
sera	NULL
from	NULL
hepatitis	NULL
B	NULL
virus-infected	NULL
humans	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:101-109	NULL
.	NULL

Milich	NULL
,	NULL
D.	NULL
R.	NULL
1987	NULL
.	NULL

Genetic	NULL
and	NULL
molecular	NULL
basis	NULL
for	NULL
T-	NULL
and	NULL
B-cell	NULL
recognition	NULL
of	NULL
hepatitis	NULL
B	NULL
viral	NULL
antigens	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

99	NULL
;	NULL
71-103	NULL
.	NULL

Milich	NULL
,	NULL
D.	NULL
R.	NULL
1989	NULL
.	NULL

Synthetic	NULL
T	NULL
and	NULL
B	NULL
cell	NULL
recognition	NULL
sites	NULL
:	NULL
implications	NULL
for	NULL
vaccine	NULL
development	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

45:195-282	NULL
.	NULL

Miller	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Robinson	NULL
.	NULL

1986	NULL
.	NULL

Common	NULL
evolutionary	NULL
origin	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
and	NULL
retroviruses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:2531-2535	NULL
.	NULL

Miyaki	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
Sato	NULL
,	NULL
T.	NULL
Gotanda	NULL
,	NULL
T.	NULL
Matsui	NULL
,	NULL
S.	NULL
Mishiro	NULL
,	NULL
M.	NULL
Imai	NULL
,	NULL
and	NULL
M.	NULL
Mayumi	NULL
.	NULL

1986	NULL
.	NULL

Integration	NULL
of	NULL
region	NULL
X	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
genome	NULL
in	NULL
human	NULL
primary	NULL
hepatocellular	NULL
carcinoma	NULL
propagated	NULL
in	NULL
nude	NULL
mice	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

67:1449-1454	NULL
.	NULL

Moriarty	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
H.	NULL
Alexander	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Lerner	NULL
.	NULL

1985	NULL
.	NULL

Antibodies	NULL
to	NULL
X-peptides	NULL
detect	NULL
new	NULL
hepatitis	NULL
B	NULL
antigen	NULL
:	NULL
serological	NULL
correlation	NULL
with	NULL
hepatocellular	NULL
carcinoma	NULL
.	NULL

Science	NULL
227:429-433	NULL
.	NULL

Nagaya	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Nakamura	NULL
,	NULL
T.	NULL
Tokino	NULL
,	NULL
T.	NULL
Tsurimoto	NULL
,	NULL
M.	NULL
Imai	NULL
,	NULL
T.	NULL
Mayumi	NULL
,	NULL
K.	NULL
Kamino	NULL
,	NULL
K.	NULL
Yamamura	NULL
,	NULL
and	NULL
K.	NULL
Matsubara	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
mode	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
DNA	NULL
integration	NULL
in	NULL
chromosomes	NULL
of	NULL
human	NULL
hepatocellular	NULL
carcinoma	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1:773-782	NULL
.	NULL

Ou	NULL
,	NULL
J.-H.	NULL
,	NULL
and	NULL
W.	NULL
Rutter	NULL
.	NULL

1985	NULL
.	NULL

Hybrid	NULL
hepatitis	NULL
B	NULL
virus-host	NULL
transcripts	NULL
in	NULL
a	NULL
human	NULL
hepatoma	NULL
cell	NULL
line	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:83-87	NULL
.	NULL

Pasek	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Goto	NULL
,	NULL
W.	NULL
Gilbert	NULL
,	NULL
B.	NULL
Zink	NULL
,	NULL
H.	NULL
Schaller	NULL
,	NULL
P.	NULL
MacKay	NULL
,	NULL
G.	NULL
Leadbetter	NULL
,	NULL
and	NULL
K.	NULL
Murray	NULL
.	NULL

1979	NULL
.	NULL

Hepatitis	NULL
B	NULL
virus	NULL
genes	NULL
and	NULL
their	NULL
expression	NULL
in	NULL
E.	NULL
coli	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
282	NULL
:	NULL
575-579	NULL
.	NULL

Persing	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
H.	NULL
E.	NULL
Varmus	NULL
,	NULL
and	NULL
D.	NULL
Ganem	NULL
.	NULL

1986	NULL
.	NULL

Antibodies	NULL
to	NULL
pre-S	NULL
and	NULL
X	NULL
determinants	NULL
arise	NULL
during	NULL
natural	NULL
infection	NULL
with	NULL
ground	NULL
squirrel	NULL
hepatitis	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

60:177-184	NULL
.	NULL

Pfaff	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Salfeld	NULL
,	NULL
K.	NULL
Gmelin	NULL
,	NULL
H.	NULL
Schaller	NULL
,	NULL
and	NULL
L.	NULL
Theilmann	NULL
.	NULL

1987	NULL
.	NULL

Synthesis	NULL
of	NULL
the	NULL
X-protein	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
in	NULL
vitro	NULL
and	NULL
detection	NULL
of	NULL
anti-X-antibodies	NULL
in	NULL
human	NULL
sera	NULL
.	NULL

Virology	NULL
158	NULL
:	NULL
456-460	NULL
.	NULL

Pugh	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
C.	NULL
Weber	NULL
,	NULL
H.	NULL
Houston	NULL
,	NULL
and	NULL
K.	NULL
Murray	NULL
.	NULL

1986	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
X	NULL
gene	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

Virol	NULL
.	NULL

20:229-246	NULL
.	NULL

ANTIGENICITY	NULL
OF	NULL
HEPATITIS	NULL
B	NULL
VIRUS	NULL
X	NULL
PROTEIN	NULL
38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

2809	NULL
Remaut	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Stannssens	NULL
,	NULL
and	NULL
W.	NULL
Fiers	NULL
.	NULL

1981	NULL
.	NULL

Plasmid	NULL
vectors	NULL
for	NULL
high-efficiency	NULL
expression	NULL
controlled	NULL
by	NULL
the	NULL
P	NULL
;	NULL
promoter	NULL
of	NULL
coliphage	NULL
no	NULL
.	NULL

1	NULL
.	NULL

Gene	NULL
15:81-93	NULL
.	NULL

Salfeld	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Pfaff	NULL
,	NULL
M.	NULL
Noah	NULL
,	NULL
and	NULL
H.	NULL
Schaller	NULL
.	NULL

1989	NULL
.	NULL

Antigenic	NULL
determinants	NULL
and	NULL
functional	NULL
domains	NULL
in	NULL
core	NULL
antigen	NULL
and	NULL
e	NULL
antigen	NULL
from	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:798-808	NULL
.	NULL

Sanger	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
Nicklen	NULL
,	NULL
and	NULL
A.	NULL
R.	NULL
Coulson	NULL
.	NULL

1977	NULL
.	NULL

DNA	NULL
sequencing	NULL
with	NULL
chain-terminating	NULL
inhibitors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
74:5463-5467	NULL
.	NULL

Schodel	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Sprengel	NULL
,	NULL
T.	NULL
Weimer	NULL
,	NULL
D.	NULL
Fernholz	NULL
,	NULL
R.	NULL
Schneider	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1989	NULL
.	NULL

Animal	NULL
hepatitis	NULL
B	NULL
viruses	NULL
,	NULL
p.	NULL
73-102	NULL
.	NULL

In	NULL
G.	NULL
Klein	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Advances	NULL
in	NULL
viral	NULL
oncology	NULL
,	NULL
vol	NULL
.	NULL

8	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Ltd.	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Seto	NULL
,	NULL
E.	NULL
,	NULL
T.	NULL
S.	NULL
B	NULL
.	NULL

Yen	NULL
,	NULL
B.	NULL
M.	NULL
Peterlin	NULL
,	NULL
and	NULL
J.-H.	NULL
Ou	NULL
.	NULL

1988	NULL
.	NULL

Trans-activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
by	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8286-8290	NULL
.	NULL

Siddiqui	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Jameel	NULL
,	NULL
and	NULL
J.	NULL
Mapoles	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
gene	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:2513-2517.	NULL
.	NULL

Spandau	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
and	NULL
C.-H.	NULL
Lee	NULL
.	NULL

1988.	NULL
frans-Activation	NULL
of	NULL
viral	NULL
enhancers	NULL
by	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62	NULL
:	NULL
427-434	NULL
.	NULL

Sprengel	NULL
,	NULL
R.	NULL
,	NULL
E.	NULL
F.	NULL
Kaleta	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1988	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
hepatitis	NULL
B	NULL
virus	NULL
endemic	NULL
in	NULL
herons	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:3832-3839.	NULL
.	NULL

Stemler	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Hess	NULL
,	NULL
R.	NULL
Braun	NULL
,	NULL
H.	NULL
Will	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
Schroeder	NULL
.	NULL

1988	NULL
.	NULL

Serological	NULL
evidence	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
polymerase	NULL
gene	NULL
of	NULL
human	NULL
hepatitis	NULL
B	NULL
virus	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

69	NULL
:	NULL
689-693	NULL
.	NULL

Twu	NULL
,	NULL
J.-S.	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Robinson	NULL
.	NULL

1989	NULL
.	NULL

Hepatitis	NULL
B	NULL
virus	NULL
X-gene	NULL
can	NULL
transactivate	NULL
heterologous	NULL
viral	NULL
sequences	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2046-2050	NULL
.	NULL

Twu	NULL
,	NULL
J.-S.	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schloemer	NULL
.	NULL

1987	NULL
.	NULL

Transcriptional	NULL
transactivating	NULL
function	NULL
of	NULL
hepatitis	NULL
B	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3448-3453	NULL
.	NULL

Van	NULL
Regenmortel	NULL
,	NULL
M.	NULL
H.	NULL
V.	NULL
1989	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
approaches	NULL
to	NULL
the	NULL
study	NULL
of	NULL
protein	NULL
antigenicity	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
10:266-272	NULL
.	NULL

Weimer	NULL
,	NULL
T.	NULL
,	NULL
J.	NULL
Salfeld	NULL
,	NULL
and	NULL
H.	NULL
Will	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
core	NULL
gene	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3109-3113	NULL
.	NULL

50a	NULL
.	NULL

Weimer	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
Weimer	NULL
,	NULL
Z.-X	NULL
.	NULL

Tu	NULL
,	NULL
M.-C.	NULL
Jung	NULL
,	NULL
G.	NULL
R.	NULL
Pape	NULL
,	NULL
and	NULL
51	NULL
.	NULL

52	NULL
.	NULL

H.	NULL
Will	NULL
.	NULL

1989	NULL
.	NULL

Immunogenicity	NULL
of	NULL
human	NULL
hepatitis	NULL
B	NULL
virus	NULL
P-gene	NULL
derived	NULL
proteins	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:3750-3756	NULL
.	NULL

Wollersheim	NULL
,	NULL
M.	NULL
,	NULL
U.	NULL
Debelka	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Hofschneider	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
transactivating	NULL
function	NULL
encoded	NULL
in	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
gene	NULL
is	NULL
conserved	NULL
in	NULL
the	NULL
integrated	NULL
state	NULL
.	NULL

Oncogene	NULL
3:545-552	NULL
.	NULL

Zahm	NULL
,	NULL
P.	NULL
,	NULL
P.	NULL
H.	NULL
Hofschneider	NULL
,	NULL
and	NULL
R.	NULL
Koshy	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
HBV	NULL
X-ORF	NULL
encodes	NULL
a	NULL
transactivator	NULL
:	NULL
a	NULL
potential	NULL
factor	NULL
in	NULL
viral	NULL
hepatocarcinogenesis	NULL
.	NULL

Oncogene	NULL
3:169-177	NULL
.	NULL

